Lung cancer remains the leading cause of cancer deaths worldwide with approximately 1.8 million deaths annually. This devastating statistic stems from a fundamental problem that most patients receive diagnosis at advanced stages when treatment options are limited and survival rates plummet dramatically. The five-year survival rate tells a stark story ranging from 90% for stage I disease to barely 10% for stage IV, highlighting how critical early detection is for improving patient outcomes.

Currently, low-dose computed tomography represents the most advanced screening tool available for lung cancer detection. The National Lung Screening Trial demonstrated that LDCT screening reduces mortality by approximately 20% compared to chest X-rays. However, this technology faces significant limitations preventing its widespread adoption as a universal screening method. The high false-positive rate of 23.3% leads to unnecessary invasive procedures and patient anxiety. Additionally, radiation exposure concerns, substantial costs and equipment accessibility issues make LDCT particularly unsuitable for screening programs in developing countries with limited healthcare resources.

The promise of biomarkers for revolutionary early detection

The urgent need for alternative screening approaches has driven intense research into biomarkers that can detect lung cancer through noninvasive body fluid analysis. According to the National Institutes of Health, a biomarker is defined as a characteristic used to measure and evaluate objectively normal biological processes, pathogenic processes or pharmacological responses to therapeutic intervention. Over the past decade, researchers have investigated numerous molecular signatures in blood, urine, saliva, sputum and exhaled breath seeking patterns that can reliably distinguish cancer patients from healthy individuals.

A groundbreaking 2024 systematic review published in Carcinogenesis analyzed 98 articles from eight databases to identify the best biomarkers for early lung cancer diagnosis. This comprehensive meta-analysis achieved a pooled area under curve of 0.85 with 95% confidence interval of 0.82-0.88, indicating that diagnostic performance of these biomarkers when combined was excellent. The study examined 30 articles on single antigen panels, 22 on autoantibodies, 31 on microRNA and RNA panels, and 15 on circulating DNA combined with conventional markers.

The development of effective biomarkers follows a rigorous four-phase validation process. Phase I involves identifying specific cancer markers by comparing tumor tissue with healthy tissue. Phase II tests whether these markers can be detected in easily obtained biological samples like blood or urine. Phase III examines whether biomarkers can identify cancer before clinical diagnosis occurs. Finally, Phase IV evaluates the screening test in real-world populations to determine false-positive rates and clinical utility.

Circulating blood proteins show remarkable diagnostic accuracy

Circulating proteins represent one of the most extensively studied biomarker categories for early lung cancer detection. These proteins can originate from cancer cell overexpression, increased secretion from diseased tissue or inflammation associated with malignancy. The CancerSEEK panel combines eight proteins including CA-125, CEA, HGF, Myeloperoxidase, OPN, Prolactin and TIMP-1, demonstrating effectiveness in distinguishing lung cancer patients from healthy controls. When integrated with circulating free DNA analysis, this protein panel shows even greater sensitivity.

Another promising approach involves measuring autoantibodies against tumor-associated antigens. Cancer cells stimulate immune responses that produce circulating autoantibodies detectable in blood samples. The EarlyCDT test measures seven autoantibodies including p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGEA4 and SOX2, and is commercially available for assessing malignancy risk in patients with solid pulmonary nodules. Clinical trials have shown this test achieves 41% sensitivity and 91% specificity in symptomatic patients with similar performance in high-risk screening cohorts.

The 2024 Carcinogenesis review identified blood biomarkers with exceptionally high sensitivities including Ciz1, exoGCC2 and ITGA2B, while CYFR21-1, antiHE4 and OPNV demonstrated high specificities. Importantly, the stability of these autoantibodies in serum allows detection through standard immunoenzymatic assays, making them practical candidates for widespread screening implementation.

MicroRNA emerges as powerful molecular messenger

MicroRNAs are small noncoding RNA molecules that regulate gene expression at the post-transcriptional level. These molecules can be aberrantly expressed in cancer and other pathological processes making them attractive biomarkers. Importantly, miRNAs demonstrate remarkable stability in various body fluids including blood, urine and sputum, and can be detected from initial tumor development through metastasis formation.

Research has identified specific miRNA panels that differentiate lung cancer patients from healthy individuals with impressive accuracy. Recent studies using next-generation sequencing to evaluate tumor-derived exosomal miRNA achieved 80.3% sensitivity and 92.3% specificity for detecting stage I non-small cell lung cancer. The miR-Test and MSC microRNA signature classifier are currently undergoing validation for clinical use. The MSC based on 24 miRNA expression ratios stratifies populations into low, intermediate or high risk categories demonstrating 87% sensitivity and 81% specificity while significantly reducing LDCT false-positive rates.

A 2025 case-control study published in Cancers evaluated a panel of serum miRNA biomarkers for lung cancer detection in 82 cancer cases and 123 controls. The researchers performed extensive literature review to shortlist 25 candidate miRNAs, with 16 showing significant two-fold increase in expression compared to controls. A final panel of six miRNA biomarkers selected with machine learning algorithms achieved a high AUC of 0.86, representing a significant step toward reducing lung cancer mortality through improved screening.

Several studies have compared miRNA levels in lung cancer patients before and after surgical resection finding significantly elevated expression of miR-21, miR-205, miR-30d and miR-24 preoperatively that decreases following tumor removal. This observation supports the potential use of miRNAs not only for early detection but also for monitoring disease recurrence after treatment.

Liquid biopsy achieves validated clinical performance

A comprehensive 2025 systematic review and meta-analysis published in the Journal of Clinical Oncology evaluated liquid biopsy diagnostic accuracy for lung cancer using data from seven trials published between 2015 and 2025. This rigorous analysis following PRISMA guidelines examined circulating tumor DNA, circulating tumor cells and extracellular vesicles to identify and track tumor markers.

The results demonstrate compelling diagnostic performance. For ctDNA, the pooled sensitivity reached 85% with specificity of 90%, indicating its superiority as a biomarker for diagnosing early-stage lung cancer. CTCs achieved sensitivity and specificity rates of 80% and 88% respectively, while EVs displayed sensitivity of 78% with specificity of 86%. Moreover, variations in ctDNA levels were associated with tumor advancement and treatment effectiveness, exhibiting a concordance rate of 92% for assessing therapeutic responses.

Circulating tumor cells represent intact cancer cells that detach from primary tumors and enter the bloodstream. Although present in extremely low concentrations typically 1-10 CTCs per milliliter of blood, their detection can provide early warning of cancer development. Remarkably, studies of patients with chronic obstructive pulmonary disease found that those testing positive for CTCs developed lung nodules 1-4 years later, suggesting CTCs may predict cancer before radiological evidence appears.

Detection methods have evolved significantly with newer fluorescence in situ hybridization approaches achieving sensitivity and specificity rates of 89-100%. The combination of CTC detection with conventional tumor markers like CEA can increase diagnostic accuracy to 84.21% sensitivity and 88.78% specificity. However, establishing efficient and reliable methods for capturing and analyzing these rare cells remains technically challenging.

Circulating tumor DNA represents another promising biomarker category. This cell-free DNA originates from dying tumor cells and typically comprises 0.01-1% of total circulating free DNA. Advanced sequencing technologies like CAPP-seq cancer personalized profiling by deep sequencing can detect ctDNA in cancer patients though levels are often lower in early-stage disease. The Lung-CLiP machine learning method which analyzes ctDNA alongside other molecular features achieved 96% specificity for lung cancer detection. Integration of ctDNA analysis with protein panels further enhances diagnostic sensitivity.

Breath tests achieve unprecedented accuracy for early detection

One of the most innovative approaches to early lung cancer detection involves analyzing volatile organic compounds in exhaled breath. Lung cancer cells produce specific VOCs that can be detected in respiratory exhalation. A groundbreaking 2025 systematic review and meta-analysis published in Clinical Biochemistry analyzed 114 articles covering 125 non-duplicate studies involving 8,768 cancer patients. This comprehensive analysis conducted in accordance with PRISMA guidelines demonstrated that VOC breath tests achieved sensitivity of 87% and specificity of 81% with an impressive area under the receiver operating characteristic curve of 0.93.

Gas chromatography combined with mass spectrometry represents the most widely used analytical method achieving sensitivity of 80% and specificity of 91% when paired with artificial neural networks. Electronic nose technology offers a more accessible and cost-effective alternative for VOC detection. These portable devices contain sensor arrays that bind volatile compounds creating unique signature patterns for different disease states.

A 2024 meta-analysis published in BMC Cancer following PRISMA guidelines analyzed data from 25 studies evaluating the effectiveness of different techniques in detecting VOCs. Studies using electronic nose technology have reported remarkable accuracy rates with some achieving 95.75% accuracy, 94.78% sensitivity and 96.96% specificity. Notably, e-nose devices have demonstrated even greater sensitivity for detecting stage I lung cancer at 92% compared to later stages at 58%, making them particularly valuable for early detection when treatment is most effective.

Recent research has extended VOC analysis beyond breath to include urinary volatile compounds. In 2023, investigators identified five specific urinary VOCs associated with early-stage lung cancer achieving 85% specificity and 90% sensitivity. This approach offers another noninvasive sampling method that could complement breath analysis for comprehensive early detection strategies.

Critical gaps and the path to clinical implementation

Despite the impressive capabilities demonstrated by various biomarker approaches, none have yet achieved the validation and standardization necessary for routine clinical implementation. Several critical gaps must be addressed to translate laboratory discoveries into practical screening tools that can save lives.

First, most biomarker studies suffer from limited sample sizes that compromise statistical power and generalizability. The validation phases require large diverse populations that reflect real-world biological variability. Additionally, many studies include predominantly advanced-stage cancer patients providing limited information about biomarker performance in detecting early disease precisely when intervention is most beneficial.

Second, standardization of collection processing and analysis protocols remains inconsistent across research centers. Different studies use varied methodologies for sample handling, storage conditions and measurement techniques making direct comparisons difficult and hindering the establishment of universal reference ranges and cutoff values. The 2024 Carcinogenesis review emphasized that further assessment is needed using appropriate sample sizes, control groups that include patients with non-malignant conditions and standardized cut-off levels for each biomarker.

Third, the combination of multiple biomarkers consistently outperforms single markers suggesting that integrated panels will likely prove most effective for clinical screening. However, determining optimal combinations requires extensive comparative studies and careful attention to cost-effectiveness and practical implementation considerations. The 2025 JCO meta-analysis demonstrated that liquid biopsy shows significant diagnostic accuracy for early diagnosis and monitoring treatment responses, highlighting its promise as a transformative instrument in clinical management.

The future of early lung cancer detection likely involves integrating multiple approaches rather than relying on any single biomarker or technology. Combining LDCT imaging with liquid biopsy panels could significantly reduce false-positive rates while improving sensitivity for early-stage disease. Studies combining microRNA signatures with LDCT have demonstrated substantial improvements in screening accuracy.

Establishing international research consortia with shared databases could accelerate biomarker validation by enabling larger studies and promoting standardized protocols. Artificial intelligence and machine learning tools offer powerful methods for integrating molecular biomarkers with clinical and epidemiological data potentially identifying patterns that enhance diagnostic accuracy beyond what any single test can achieve.

For biomarkers to achieve global impact they must be not only accurate but also affordable and implementable in resource-limited settings. This requirement favors technologies like electronic nose devices or simple immunoassays over expensive sequencing methods. Cost-effectiveness analyses comparing various screening strategies will be essential for guiding public health policy and resource allocation.

Conclusion

Early lung cancer detection represents one of the most critical challenges in oncology. While current screening methods show promise they remain limited by cost, accessibility and accuracy concerns. The extensive 2024-2025 research into biomarkers including proteins, autoantibodies, microRNAs, circulating tumor cells, circulating tumor DNA and volatile organic compounds demonstrates remarkable potential for revolutionizing early detection through noninvasive testing.

The journey from laboratory discovery to clinical implementation requires overcoming significant challenges including standardization, validation in large diverse populations and demonstration of cost-effectiveness. Success will likely come through integrated approaches combining multiple biomarkers with imaging technologies supported by artificial intelligence tools that can extract maximum diagnostic value from complex molecular data.

As research continues and technologies mature the vision of routine accessible accurate lung cancer screening becomes increasingly achievable. Such advances promise to transform lung cancer from a disease typically diagnosed at advanced stages to one detected and treated early dramatically improving survival rates and reducing the global burden of this devastating illness.

References

1. Mohamed E, García Martínez DJ, Hosseini MS, et al. Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis. Carcinogenesis. 2024;45(1-2):1-22.
2. Jin MJ, Li EM, Xu LY. Diagnostic accuracy of breath tests based on volatile organic compounds for cancer: A systematic review and meta-analysis. Clin Biochem. 2025;136:110898.
3. Agrawal A, Sofia A, Manoharan MP, Fernandes BCA, Maroules M. Liquid biopsy for early detection and monitoring of lung cancer: A systematic review and meta-analysis. J Clin Oncol. 2025;43(16_suppl):e20019.
4. Fan X, Zhong R, Liang H, et al. Exhaled VOC detection in lung cancer screening: a comprehensive meta-analysis. BMC Cancer. 2024;24:775. doi:10.1186/s12885-024-12537-7
5. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation. J Exp Clin Cancer Res. 2024;43:96.
6. Gao Y, Chen B, Cheng X, et al. Development of a miRNA-Based Model for Lung Cancer Detection. Cancers. 2025;17(6):942.
7. National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer. Accessed January 2025.
8. Centers for Disease Control and Prevention. Lung Cancer Screening. Updated 2024.